The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll …
To buy or not to buy, that’s the question. For even the most seasoned Wall Street observers, determining the ideal time to pull …
In the stock market, sometimes all it takes is a single catalyst to propel shares to sky-high levels. This is especially common with …
In a research note issued Wednesday, H.C.
Friday turned out to be a nightmare for DURECT Corporation (NASDAQ:DRRX) investors, after the drug maker announced that its pain relief candidate Posimir failed …
Earlier this week, DURECT Corporation (NASDAQ:DRRX) announced an exclusive U.S.
DURECT Corporation (NASDAQ:DRRX) investors cheer the news that the company has achieved positive biomarker readout from DUR-928 Phase 1b trial in nonalcoholic steatohepatitis …
Yesterday, DURECT Corporation’s (NASDAQ:DRRX) licensee Pain Therapeutics announced that it had received a complete response letter (CRL) from the FDA for the resubmitted …
DURECT Corporation (NASDAQ:DRRX) is watching its shares tank nearly 30% in Monday’s session after receiving a Complete Response Letter from the U.S.
On August 1st, biotech firm DURECT Corporation (NASDAQ:DRRX) released its second quarter financial results for this year. In reaction, Rodman & Renshaw analyst …
